Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
7
|
pubmed:dateCreated |
1996-12-16
|
pubmed:abstractText |
Studies using dry powder devices have suggested that fluticasone propionate (FP) has a greater systemic effect than budesonide (BUD). The aim of the present study was to investigate and compare the relative systemic potency of FP and BUD from their respective pressurized metered-dose inhalers (pMDIs). A placebo-controlled, open, randomized, cross-over study was conducted in 21 healthy male volunteers. Placebo, BUD (200, 400 and 1,000 micrograms b.i.d.) and FP (200, 375 and 1,000 micrograms b.i.d.) were inhaled for 4 days, with a wash-out period of at least 3 days between treatments. Blood samples for cortisol analysis were drawn during the last 24 h of each treatment period. Cortisol levels, measured as 24 h pooled plasma cortisol, were statistically significantly lower (p = 0.0001) for all dose levels during FP pMDI treatment (21, 39 and 84% suppression from placebo) than during BUD pMDI treatment (1, 3 and 27% suppression from placebo). The relative systemic potency FP:BUD was 3.7:1 (95% confidence interval (95% CI) 2.9-4.8)). The relative systemic potency based on the single 08:00 h samples was 5.2:1 (95% CI 3.0-9.3). In conclusion, in healthy male volunteers using pressurized metered-dose inhalers, fluticasone propionate was shown to have a stronger systemic effect than budesonide.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Aerosols,
http://linkedlifedata.com/resource/pubmed/chemical/Androstadienes,
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Inflammatory Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Budesonide,
http://linkedlifedata.com/resource/pubmed/chemical/Hydrocortisone,
http://linkedlifedata.com/resource/pubmed/chemical/Pregnenediones,
http://linkedlifedata.com/resource/pubmed/chemical/fluticasone
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0903-1936
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
9
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1427-32
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:8836654-Administration, Inhalation,
pubmed-meshheading:8836654-Administration, Topical,
pubmed-meshheading:8836654-Adult,
pubmed-meshheading:8836654-Aerosols,
pubmed-meshheading:8836654-Androstadienes,
pubmed-meshheading:8836654-Anti-Inflammatory Agents,
pubmed-meshheading:8836654-Budesonide,
pubmed-meshheading:8836654-Cross-Over Studies,
pubmed-meshheading:8836654-Dose-Response Relationship, Drug,
pubmed-meshheading:8836654-Humans,
pubmed-meshheading:8836654-Hydrocortisone,
pubmed-meshheading:8836654-Male,
pubmed-meshheading:8836654-Nebulizers and Vaporizers,
pubmed-meshheading:8836654-Pregnenediones,
pubmed-meshheading:8836654-Radioimmunoassay
|
pubmed:year |
1996
|
pubmed:articleTitle |
Assessment of the relative systemic potency of inhaled fluticasone and budesonide.
|
pubmed:affiliation |
Astra Pharmaceutica BV, Zoetermeer, The Netherlands.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|